
Hypoxia-inducible factor (HIF) stabilizers are approved to treat the anaemia of chronic kidney disease in different regions worldwide. However, regulatory agencies have raised concerns regarding cardiovascular safety. A puzzling observation is that the safety signal from HIF stabilizers concerning major adverse cardiovascular events (MACE) has ranged from potential protection to neutral to potential harm in diverse clinical trials, even for the same agent, without a clear explanation.
Like
Save
Share